Frontiers
US$ 21.78
retatrutide phase 2 obesity trial Weight loss with as compared to currently licenced Eli Lilly infiltrates anti-obesity market
Description
March 5, 2025
2024;385:e078852
Cardiologists recommended combined therapy for patients with established cardiovascular disease or high cardiovascular risk who were already on treatment with one of the two drugs and had an HbA1c above target
The platform connects eligible adults across four health programs - weight loss, hair growth, sexual health, and NAD+ therapy - and does so through a named, verifiable provider group and a named, verifiable pharmacy network
Deanfield, S.E
Fewer hot flashes and night sweats
